S&P Futures
6,046.25 +8.00 (+0.13%) Dow Futures
45,023.00 +72.00 (+0.16%) Nasdaq Futures
21,013.25 +19.75 (+0.09%) Russell 2000 Futures
2,442.30 +9.90 (+0.41%) Crude Oil
68.79 +0.02 (+0.03%) Gold
2,639.10 +17.80 (+0.68%)
ZyVersa Therapeutics, Inc. (ZVSA)
After hours:
| Previous Close | 1.1100 |
| Open | 1.1200 |
| Bid | 1.0000 x 100 |
| Ask | 1.1300 x 100 |
| Day's Range | 1.0500 - 1.1347 |
| 52 Week Range | 1.0400 - 42.3500 |
| Volume | |
| Avg. Volume | 1,252,577 |
| Market Cap | 2.508M |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 0.00 |
| EPS (TTM) | 491.9700 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- Zacks Small Cap Research
OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR
NASDAQ:ZVSA Anthony Kraus: Hello, and welcome to Virtual Investor Conferences. My name is Anthony Kraus, and on behalf of OTC markets, as well as our co-host, Zacks Small Cap Research, we're very pleased you have joined us for our next live presentation from ZyVersa Therapeutics, Inc. Their session will be moderated by Brad Sorensen, senior Equity Research Analyst with Zacks Small Cap Research.
GlobeNewswireZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.The published data sho
